FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Regenxbio said on ​Monday the U.S. Food ‌and Drug Administration has placed its experimental gene therapy for Hunter ​syndrome on clinical hold ​after spinal scans found abnormalities ⁠in five study p...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。